San Francisco Sentry Investment Group’s Orexigen Therapeutics, Inc. OREX Stock Holding History

San Francisco Sentry Investment Group’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-250	Closed	-$16K	–	705
2014 Q1	$16K	Hold	250	–	–	0.01%	476
2013 Q4	$14K	Hold	250	–	–	﹤0.01%	463
2013 Q3	$15K	Hold	250	–	–	0.01%	436
2013 Q2	$15K	Buy	+250	New	+$15.4K	0.01%	439

Other funds holding OREX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

San Francisco Sentry Investment Group's OREX Position: Q2 2014 in Review

San Francisco Sentry Investment Group sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2014, closing a stake of 250 shares — an estimated $16K sold.

San Francisco Sentry Investment Group first reported a position in OREX in Q2 2013 and held it in 4 quarters. The position peaked at $16K in Q1 2014. 129 funds tracked by Wall St. Rank hold OREX as of Q2 2014.

San Francisco Sentry Investment Group reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2014 after selling out during the quarter.
San Francisco Sentry Investment Group sold 250 Orexigen Therapeutics, Inc. shares in Q2 2014, an estimated $16K.
San Francisco Sentry Investment Group first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 4 quarters.
San Francisco Sentry Investment Group's Orexigen Therapeutics, Inc. position peaked at $16K in Q1 2014.
129 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2014.

Based on San Francisco Sentry Investment Group's 13F filing for Q2 2014, filed 18 Jul 2014.